LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook
LifeStance reported Q3 2026 revenue of $455.9 million, up 25% year-over-year, with net income of $22.4 million versus $1.1 million a year ago. Adjusted EBITDA rose 70% to $68.4 million (15.0% of revenue), Center Margin grew 38% to $161.4 million, and visit volumes increased 17% to 2.7 million on an 11% larger clinician base. Management raised full-year 2026 guidance across all metrics — revenue to $1.741B-$1.761B and Adjusted EBITDA to $242M-$250M — citing momentum in TMS and Spravato plus improving operating leverage.
Key figures
- Eps
- 0.06
- Revenue
- 455900000
- Guidance
- FY26 revenue $1.741B-$1.761B (raised), Center Margin $599M-$613M, Adjusted EBITDA $242M-$250M; Q4 revenue $446M-$466M
- Revenue Yoy
- 25%
- Fcf
- 22400000
- Visits
- 2.7 million (+17% YoY)
- Clinicians
- 8863
- Net income
- 22400000
- Center margin
- 161400000
- Adjusted ebitda
- 68400000
- Net long term debt
- 255500000
- Cash and equivalents
- 218800000
- Adjusted ebitda margin
- 15.0%
- Operating cash flow q3
- 37000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.